Antiphospholipid antibodies (aPL), the majority of which are directed against β 2 -glycoprotein I (β 2 GPI), are associated with an increased incidence of venous and arterial thrombosis. The pathogenesis of antiphospholipid/anti-β 2 GPI-associated thrombosis has not been defined, and is likely multifactorial. However, accumulating evidence suggests an important role for endothelial cell activation with the acquisition of a procoagulant phenotype by the activated endothelial cell. Previous work demonstrated that endothelial activation by antiphospholipid/anti-β 2 GPI antibodies is β 2 GPI-dependent. We extended these observations by defining annexin A2 as an endothelial β 2 GPI binding site. We also observed that annexin A2 plays a critical role in endothelial cell activation induced by anti-β 2 GPI antibodies, and others have described direct endothelial activation by anti-annexin A2 antibodies in patients with aPL . Similar findings have been reported using human monocytes, which also express annexin A2. Because annexin A2 is not a transmembrane protein, how binding of β 2 GPI/anti-β 2 GPI antibodies, or anti-annexin A2 antibodies, to endothelial annexin A2 causes cellular activation is unknown. Recent studies, however, suggest an important role for the Toll-like receptor family, particularly TLR4. In this article, we review the role of these interactions in the activation of endothelial cells by aPL . The influence of these antibodies on the ability of annexin A2 to enhance t-PA-mediated plasminogen activation is also discussed. Lupus (2008) 17, 943-951.
Introduction
The antiphospholipid syndrome (APS) is among the most important of the acquired thrombophilic states. This disorder is associated with an increased risk of primary arterial and venous thrombosis, and its persistence after an initial vascular event increases the risk for recurrent thrombosis and cardiovascular mortality. 1 Despite the clinical significance of the APS, its overall pathogenesis is not well understood. 2 Pathogenic mechanisms may vary among patients, and it is likely that in most affected individuals the pathogenesis of thrombosis is multifactorial.
Endothelial cells play an essential role in maintaining blood fluidity through the expression of naturally occurring anticoagulants on the endothelial cell surface. 3, 4 Disruption or activation of endothelial cells leads to loss of the anticoagulant phenotype and assumption of pro-inflammatory, prothrombotic properties. [4] [5] [6] Many reports have shown that antiphospholipid antibodies (aPL) may activate endothelial cells in vitro 2,7-9 and this appears to occur in vivo as well. 10 These considerations support the hypothesis that endothelial cell activation plays a prominent role in the pathogenesis of the APS. Moreover, because many of the reported pathogenic activities of aPL may occur indirectly as a consequence of endothelial cell activation, activation of endothelial cells may be a primary event in the pathophysiological cascade leading to thrombus development in patients with APS.
We have previously reported that annexin A2, a member of a large family of annexin proteins, serves as an endothelial cell binding site for the antiphospholipid cofactor, β 2 -glycoprotein I (β 2 GPI). 11 Additional studies suggest that binding of β 2 GPI to endothelial cell annexin A2 plays a critical role in subsequent activation of endothelial cells by anti-β 2 GPI antibodies. 7 Moreover, anti-annexin A2 antibodies that are capable of directly activating endothelial cells also occur in patients with APS. 12 Human monocytes also express annexin A2, and their activation may also contribute to the pathogenesis of the APS. In this report, we will provide a brief review of the biology of annexin A2, and discuss its potential role in antiphospholipid/ anti-β 2 GPI-antibody-mediated thrombosis.
Annexin A2
Overview The annexins comprise a large family of structurally related proteins, which share the ability to bind to negatively charged phospholipids in a Ca 2+dependent manner. 13 This binding is reversible, and chelation of Ca 2+ liberates annexins from the phospholipid matrix. Each member of the annexin family is composed of two principal domains: a unique amino-terminal "tail" domain, and a conserved COOH-terminal protein core 13 (Figure 1 ). The latter, which consists of a series of 70 amino acid 'endonexin' repeats, shares approximately 40-70% homology among annexin family members and mediates the binding of annexins to phospholipid and cell membranes. 14 This domain also contains F-actin binding and bundling sites, as well as heparin binding sites. 15 Unlike the core domain, the length and amino acid composition of the tail domain is highly variable among different annexins. 14 Unlike most annexins, and despite the lack of a hydrophobic signal peptide, the presence of annexin A2 on cell surfaces is well established; 14 approximately 4.3% of total endothelial annexin A2 is associated with the external plasma membrane. 16 Association of annexin A2 with the cell surface is thought to be mediated by a KGLGT sequence (residues 118-122) and a coordinating D161 residue that reside within endonexin core repeat 2. 13, 16 Annexin A2 mediates a number of activities that regulate several cellular functions. For example, annexin A2 binds F-actin and mediates Ca 2+dependent filament bundling. 13, 18 These effects may play an important role in the organization of membrane-associated actin at sites of cholesterol-rich membrane domains (lipid rafts), in which annexin A2 may be concentrated. 19 Indeed, in the presence of Ca 2 + , annexin A2 binds to and may promote the lateral association as well as the organization of such glycosphingolipid and cholesterol-rich lipid microdomains, 20,21 a property that may require association of annexin A2 with the actin cytoskeleton. 13 This property may also underlie the potential contributions of annexin A2 to endo and exocytotic pathways. 22 Annexin A2 mediates the binding of β 2 -glycoprotein I (β 2 GPI) to endothelial cells Most pathogenic aPL, detected either by their ability to prolong phospholipid-dependent anticoagulation tests (lupus anticoagulants; LAC) or their binding to cardiolipin-coated wells (anticardiolipin antibodies: ACA), are directed against β 2 GPI. 2,23-26 A subset of patients with clinical characteristics of the APS but negative tests for LAC or ACA may have antiβ 2 GPI antibodies detected only by a direct antiβ 2 GPI ELISA. 27, 28 Such antibodies have recently been incorporated into the laboratory criteria for the APS. 1 β 2 GPI is an abundant plasma glycoprotein, first described by Schulze, et al. in 1961, 29 that consists of five homologous 60-amino acid domains. 30 The first four of these are classical short consensus repeat domains with extensive homology to those found in the complement-type repeats of Factor H. 31 Each of these contains four conserved cysteines with a characteristic C 1-3 , C 2-4 disulfide bonding pattern, whereas domain 5 contains six cysteines, with C 1-4 , C 2-5 and C 3-6 disulfide linkages. [32] [33] [34] Domain 5 is also unique in its high content of lysine residues 35, 36 that mediate the binding of β 2 GPI to anionic phospholipids. 36, 37 Dimerization of β 2 GPI, which may be induced by bivalent anti-β 2 GPI antibodies, dramatically enhances its phospholipid binding activity. 38 Previous studies from our laboratory focused on the interactions of β 2 GPI with endothelial cells, and led to the identification of annexin A2 as a high affinity endothelial cell surface β 2 GPI binding protein. 11 We reported that 125 I-β 2 GPI bound with high affinity (K d~1 8 nM) to unstimulated human umbilical vein Figure 1 Structure of the annexin A2:S100A10 heterotetramer. The S100A10 (p11) protein is shown binding to the annexin A2 tail domain. 1-4 represents the four annexin repeats within the core domain. Tyrosine and serine phosphorylation sites are present within the tail domain (from Brownstein, et al. 17 ). endothelial cells (HUVEC), and subsequently used an affinity purification strategy, with β 2 GPI as the immobilized ligand, to isolate β 2 GPI binding proteins of approximately 36 and 78 kDa from HUVEC. Analysis of tryptic digests of these proteins by LC-MS showed peptide sequences exclusively corresponding to those within annexin A2. A role for annexin A2 in binding of β 2 GPI to cells was confirmed in subsequent studies, in which we reported that 1) binding of β 2 GPI to endothelial cells was blocked by monoclonal and polyclonal anti-annexin A2 antibodies, 2) transfection of HEK-293 cells with annexin A2 cDNA led to a 10-fold increase in binding of 125 I-β 2 GPI and 3) high affinity binding of β 2 GPI and annexin A2 to each other also occurred in cell free systems, including ELISA and surface plasmon resonance assays. 11 The role of β 2 GPI-annexin A2 interactions in endothelial cell activation Activation of endothelial cells may play a central role in the development of thrombosis in patients with APS, 2,38-42 and several reports have showed that plasma from patients with the APS contains antibodies that bind and activate endothelial cells. [8] [9] [10] 43, 44 Moreover, endothelial cell activation by such antibodies was shown by Simantov, et al. 8 to occur in a β 2 GPI-dependent manner. The possible clinical relevance of endothelial cell activation in patients with APS is supported by reports showing increased plasma levels of tissue factor 45 and VCAM-1, 46 as well as endothelial microparticles, 47, 48 in these individuals.
Previous studies performed in our laboratory have demonstrated that antiphospholipid/anti-β 2 GPI antibodies activate endothelial cells through cross-linking or clustering of annexin A2-bound β 2 GPI on the endothelial surface. 7 This conclusion is based on several observations. First, both intact anti-annexin A2 antibodies and anti-annexin A2-derived F(ab') 2 fragments (bivalent) induced endothelial cell activation, whereas anti-annexin A2 Fab fragments (monovalent) did not. Second, the magnitude and time course of endothelial cell activation induced by anti-annexin A2 antibodies or anti-β 2 GPI antibodies in the presence of β 2 GPI was indistinguishable. Third, anti-annexin A2 antibodyderived Fab fragments (monomeric) blocked endothelial cell activation caused by intact anti-annexin A2 antibodies, as well as that caused by anti-β 2 GPI antibodies in the presence of β 2 GPI. These results suggest that annexin A2 clustering induced by either bivalent anti-annexin A2 antibodies or F(ab') 2 fragments, or bivalent anti-β 2 GPI antibodies in the presence of annexin A2-bound β 2 GPI, induces endothelial cell signalling responses that lead to endothelial cell activa-tion and expression of the endothelial cell adhesion molecules E-selectin, VCAM-1 and ICAM-1. 7 These observations are supported by a subsequent report from Cesarman-Maus, et al. 12 that described anti-annexin A2-specific antibodies in patients with the APS, which also induced endothelial cell activation. In this study, serum samples from 434 individuals (206 patients with lupus, 62 with APS, 21 with nonautoimmune thrombosis and 145 normal controls) were evaluated for the presence of anti-annexin A2 antibodies by ELISA and/or immunoblotting. Antiannexin A2 antibodies were detected in three of the 145 normal controls (2.1%) and in 6.3% of patients with systemic lupus who had not had thrombosis. Anti-annexin A2 antibodies were not detected in any patients with thrombosis associated with hereditary thrombophilia or acquired non-immune risk factors. On the contrary, anti-annexin A2 antibodies (>3 SD) were observed in 22.6% of patients with APS, including 17.5% of patients with venous, 29.4% of patients with arterial and 40% of patients with mixed thrombosis. Antibodies occurred with equal frequency in patients with primary and secondary APS, but were significantly more common (25.8%) in patients with lupus-associated APS than in patients with lupus who had not experienced thrombosis (6.3%). Antiannexin A2 IgG from these patients induced endothelial cell activation, enhancing the expression of endothelial cell tissue factor by 6.4-fold. 12 How does annexin A2 clustering induce endothelial cell activation?
The mechanisms by which cross-linking of annexin A2-bound β 2 GPI by anti-β 2 GPI antibodies, or direct cross-linking of annexin A2 by anti-annexin A2 antibodies induces endothelial cell activation has not been clearly defined. Although annexin A2 may be phosphorylated by pp60 c-src in response to membrane binding, 49 and has been implicated in insulin signal transduction, 50 it is not a transmembrane protein and the mechanisms by which it might induce outside-in signalling events in response to binding of β 2 GPI and anti-β 2 GPI antibodies is not obvious. In previous studies, we postulated that a transmembrane 'adaptor' protein that associates laterally with annexin A2 in the cell membrane might facilitate transmembrane signal transduction. 11 Although this hypothesis has been received with some skepticism, accumulating evidence supports the involvement of additional cellular protein(s) in mediating endothelial cell activation in response to anti-β 2 GPI antibodies. However, the exact mechanisms by which β 2 GPI and anti-β 2 GPI antibodies activate endothelial cells have yet to be fully delineated.
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Clues to potentially relevant signalling pathways are provided by consideration of current knowledge concerning signalling pathways responsible for endothelial activation, and reports that have examined endothelial cell activation in response to anti-β 2 GPI antibodies. As noted previously, endothelial cells activated by anti-β 2 GPI antibodies in the presence of β 2 GPI, or directly by anti-annexin A2 antibodies, show increased cell surface expression of adhesion molecules, including ICAM-1, VCAM-1 and Eselectin, 7, 8 as well as tissue factor. Similar responses that occur in response to inflammatory cytokines such as tumour necrosis factor alpha (TNFα) depend upon NFκB-dependent gene transcription, which occurs following release of NFκB from IκB and its translocation to the nucleus. [51] [52] [53] [54] Dunoyer-Geindre, et al. 55 were the first to show that incubation of endothelial cells with anti-β 2 GPI antibodies led to nuclear translocation of NFκB that was linked to expression of endothelial cell tissue factor, ICAM-1, VCAM-1 and E-selectin. These investigators also reported that BAY11-7085, which inhibits NFκB nuclear translocation, blocked the increased expression of adhesion molecules caused by anti-β 2 GPI antibodies, confirming a central role for NFκB in the endothelial cell activation response to these antibodies. 55 An important outside-in signalling pathway that culminates in NFκB activation is that triggered by ligand binding through toll-like receptor (TLR) family members, particularly TLR4. [56] [57] [58] [59] The cytoplasmic domains of this family of transmembrane 'pattern recognition' receptors displays extensive homology to those of the interleukin-1 receptor (IL-1R) family, thus leading to their designation as Toll/IL-1R (TIR) domains. 56 At least 10 distinct TLR family members have been identified in humans, 56, 57 with TLR-4 serving as the primary lipopolysaccharide (LPS) signalling receptor. Through CD14, LPS is transferred to the receptor complex of TLR-4 and an adaptor protein, MD2, upon which a cascade of signalling events culminating in NFκB activation ensues ( Figure 2 ). 60 Definition of this pathway has been aided by studies in the C3H/HeJ mouse strain, in which the tlr4 gene contains a missense mutation in the region encoding the cytoplasmic tail (A to C substitution at position 2342), which results in the change of a highly conserved proline to histidine at position 712, and a loss of responsiveness to LPS. 61 The loss of TLR4 signalling in response to LPS renders these animals resistant to LPS challenge. 61 Direct evidence for a role of the TLR4 signalling pathway in activation of endothelial cells by antiβ 2 GPI antibodies was first provided by Raschi, et al. 62 . These investigators compared the ability of dominant negative constructs of MyD88 (myeloid differentiation protein) Traf2 (TNF receptor-associated factor 2) and Traf6 (TNF receptor-associated factor 6) to block NFκB activation (determined using a reporter gene, ELAM-NFκB-luciferase) in an immortalized endothelial cell line, HMEC-1, in response to IL-1, TNFα, LPS and anti-β 2 GPI antibodies. They observed that the pattern of inhibition caused by these dominant negative transfectants was similar when IL-1, LPS or anti-β 2 GPI antibodies were used as the agonist (i.e., ΔTraf6 and ΔMyD88 were effective inhibitors, whereas ΔTraf2 was not; the latter inhibited TNFα-induced activation only, because of the association of Traf2 with the TNFα receptor). These results suggested that anti-β 2 GPI antibodies use a MyD88-dependent pathway for cellular activation. Moreover, these investigators also reported that anti-β 2 GPI antibodies, IL-1 and LPS induced phosphorylation of IRAK, one of the initial kinases recruited by receptors of the IL-1/TLR superfamily. However, although the kinetics of phosphorylation caused by LPS and anti-β 2 GPI antibodies were virtually identical, IL-1 induced more rapid phosphorylation of IRAK. 63 Moreover, specific IL-1R antagonists did not block NFκB activation caused by anti-β 2 GPI antibodies. Taken together, these results supported a role for TLR4, as opposed to the IL-1R, as the relevant receptor involved in antiβ 2 GPI-dependent cellular activation. This conclusion is interesting, as peptides derived from β 2 GPI share similarities in amino acid sequences and perhaps structure with common bacteria and viruses, 64 and because common microbial structures are natural ligands for the TLR family of receptors. 65 Other studies (vide infra) support the hypothesis that interactions between TLR4 and β 2 GPI contribute to endothelial cell activation induced by anti-β 2 GPI antibodies, although at this point it is uncertain whether β 2 GPI binds to TLR4 directly or through interactions involving other proteins, one of which may be annexin A2.
In a subsequent report, Pierangeli, et al. 66 assessed the potential relevance of TLR4 signalling to endothelial cell activation induced by anti-β 2 GPI antibodies in vivo. These investigators compared the ability of IgG fractions from two patients with APS, one patient with aPL negative systemic lupus erythematosus and one normal individual to induce leukocyte adhesion to the vasculature and thrombosis in a murine cremasteric post-capillary venule model performed in wild type and C3H/HeJ LPS −/− mice (containing the TLR4 mutation described above). 61 In wild-type mice, IgG fractions from patients with APS significantly increased thrombus size as well as the number of leukocytes adherent to the endothelium, although similar changes were not observed in LPS −/− mice or in wild-type mice treated with β 2 GPIdepleted IgG fractions from the patients with APS. Tissue factor activity was also increased in carotid homogenates from wild-type, but not in LPS −/− mice that had been treated with the APS IgG fractions. 66 In a parallel study, the authors also determined the incidence of the Asp299Gly and Thr399Ile polymorphisms in the tlr4 gene in 110 patients with APS. These polymorphisms, which cosegragate, have been associated with a decreased response to LPS in humans. 67, 68 In these studies, heterozygosity for the polymorphism was significantly less frequent in patients with the APS than in normal controls (4.5% vs 11%, respectively), suggesting that the wild-type allele, associated with greater TLR4 activity, might contribute to manifestations of the APS. These interesting studies, in both murine models as well as humans, suggest a potentially important role for TLR4 in the pathogenesis of the APS.
Despite these insightful studies, the mechanism by which binding of β 2 GPI to cells ultimately leads to cellular activation remains uncertain. Our studies suggest a role for annexin A2, potentially in concert with an adaptor protein such as TLR4. 7 The studies of Raschi 62 and Pierangeli 66 confirm the involvement of TLR4, in vitro and in vivo. However, there is little information available concerning the potential interaction between annexin A2 and TLR4, although in preliminary studies, we reported that TLR4 could be immunopurified from extracts of endothelial cells using a column of immobilized annexin A2. 69 Sorice, et al. 70 have examined the cellular interactions of β 2 GPI and TLR4 in more detail using isolated human monocytes, which also express abundant annexin A2. These investigators reported that annexin A2 and β 2 GPI co-immunoprecipitated in the Triton X-100 insoluble lipid raft fraction derived from these cells. Moreover, anti-β 2 GPI antibodies induced a relative shift of TLR4 from the Triton X-100-soluble to the Triton X-100-insoluble fractions. β 2 GPI could be coimmunoprecipitated from Triton X-100 insoluble fractions by anti-TLR4 antibodies, and the association between these two proteins was disrupted by methylβ-cyclodextrin, which disrupts lipid rafts. Anti-β 2 GPI antibodies increased levels of active p65 and p50 and induced IRAK phosphorylation. Interestingly, although the MEK inhibitor PD98059 significantly inhibited anti-β 2 GPI-induced expression of tissue factor and release of TNFα, PD98059 inhibited activation of NFκB only slightly. 70 These results suggest that these antibodies activate two distinct signalling pathways that each contribute to the activated cellular phenotype. All the β 2 GPI found in association with the Triton X-100-insoluble fractions in this study migrated at approximately 100 kD, an unusual finding attributed to β 2 GPI oxidation and dimerization. It was suggested that dimerization of β 2 GPI might induce the cellular activation state directly by inducing receptor clustering.
In summary, although the details of the pathways through which anti-β 2 GPI antibodies cause cellular activation have not been fully delineated, important roles for annexin A2 and TLR4 are suggested by evidence from several sources. Activation of the TLR4initiated MyD88-dependent pathway as well as the MEK-1/ERK pathway may both be involved in the outside-in signalling events that lead to cellular activation. The relative importance of these pathways may vary depending on the cell type (endothelial cell, monocyte). The nature of the biochemical interactions between annexin A2, β 2 GPI, TLR4 and perhaps additional proteins have yet to be fully defined.
Does β 2 GPI affect fibrinolysis?
Annexin A2 and the annexin A2-S100A10 heterotetramer are endothelial cell receptors for plasminogen and tissue-type plasminogen activator. 71, 72 Binding of t-PA (K d~3 0 nM) and plasminogen (K d~1 14 nM) to annexin A2 enhances plasmin generation by facilitating co-assembly of these reactants, and lowering the K M for their interaction. 71, 73 Annexin A2 mediates the binding of t-PA to endothelial cells through interactions with an LCKLSL sequence in the annexin A2 tail domain, 74 whereas plasminogen has been reported to bind annexin A2 through an internal lysine residue (K307) exposed following annexin A2 proteolysis. 71 Plasminogen also binds the annexin A2:S100A10 heterotetramer via the S100A10 protein, which contains a C-terminal lysine. 75, 76 Annexin A2 enhances the catalytic efficiency of t-PA-mediated plasminogen activation on cell surfaces by approximately 60-fold; 77 this effect is inhibited in the presence of Lys analogues or carboxypeptidase B. More potent enhancement of t-PA-mediated plasminogen activation (approximately 341-fold) is mediated by the annexin A2: S100A10 heterotetramer. 75, 76 Several studies suggest an important physiological role for annexin A2 in fibrinolysis. 78 For example, homozygous annexin A2-null mice develop areas of fibrin deposition in the microvasculature of several organs, and display impaired clearance of injuryinduced arterial thrombi. 79 Annexin A2 is abundantly expressed on the surface of human monocytes and mediates plasminogen-dependent matrix invasion by these cells, 80 and patients with acute promyelocytic leukemia, in whom annexin A2 is expressed on the surface of malignant leukemic cells, develop a hyperfibrinolytic syndrome. 81 In rats, arterial thrombosis induced by oxidative injury to the vasculature caused by ferric chloride can be significantly attenuated by pretreatment with intravenous annexin A2. 82 The ability of annexin A2 to function as a binding site for β 2 GPI, a target for anti-annexin A2 antibodies, and a facilitator of endothelial cell surface fibrinolysis suggests that impairment of the latter activity by β 2 GPI and/or anti-β 2 GPI antibodies might result in diminished fibrinolytic activity. Indeed, Cesarman-Maus, et al. have reported that anti-annexin A2 antibodies isolated from patients with APS inhibit t-PA-dependent plasminogen activation in the presence of annexin A2 by 19-71%, independently of β 2 GPI (Figure 3 ). These antibodies also inhibit cell surface plasmin generation on endothelial cells by 34-83%. 12 However, addition of β 2 GPI to the system creates a more complex scenario, because β 2 GPI itself may enhance the activation of plasminogen. Lopez-Lira, et al. 83 have reported that β 2 GPI binds gluplasminogen and stimulates streptokinase-mediated plasminogen activation. These investigators also reported an increase in plasmin generation on the surface of a human microvascular endothelial cell line (HMEC-1) following incubation with β 2 GPI. 83 These observations suggest that binding of β 2 GPI to endothelial cells may lead to enhancement of cell surface fibrinolytic activity, although whether such an effect is mediated through binding of β 2 GPI to annexin A2 has not been addressed. We have also recently observed that β 2 GPI may directly stimulate t-PA-dependent plasminogen activation, even in the absence of annexin A2, and that this activity may be inhibited by anti-β 2 GPI antibodies a . The mechanisms by which these effects occur are currently under study.
Additional considerations suggest a role for β 2 GPI in regulation of fibrinolysis through pathways that may involve annexin A2 only indirectly. For example β 2 GPI has been reported to bind fibrin, and thus may potentially stimulate the binding of plasminogen to fibrin clots. 83 Yasuda, et al. have reported that nicked β 2 GPI, which has been cleaved by plasmin between Lys317 and Thr318 in domain 5, but not intact β 2 GPI, binds to glu-plasminogen (K d = 0.37 μM) and suppresses plasmin generation in the presence of t-PA, plasminogen and fibrin. 84 Takeuchi, et al. 85 reported decreased fibrinolysis in euglobulin fractions from patients with APS, attributing this effect to impaired factor XII activation. β 2 GPI has also been reported to protect t-PA from inhibition by plasminogen activator inhibitor type 1 (PAI-1), an activity blocked by monoclonal aPL . 86 
Conclusions
Annexin A2 plays an important role in the pathogenesis of the APS. It is an important binding site for β 2 GPI on the surface of endothelial cells and monocytes, and cross linking or clustering of annexin A2bound β 2 GPI leads to cellular activation with expression of a procoagulant phenotype and inflammatory cytokines. This interaction may also depend upon TLR4, although whether β 2 GPI binds to TLR4 directly or only via annexin A2 or other cellular proteins is unknown. Similar mechanisms may operate on monocytes and endothelial cells, although the relative importance of MyD88-dependent versus MEK-1/ERK signalling pathways is uncertain. Additional work defining these pathways in vitro and in vivo is likely to yield new therapeutic insights for treatment of the APS. For example, it is possible that pharmacologically disrupting the interaction between β 2 GPI and annexin A2, β 2 GPI and TLR4, or the assembly of a signalling complex that contains these proteins, and perhaps others, may modulate the pathophysiologic signalling events responsible for acquisition of the procoagulant phenotype in patients with the APS. The roles of additional β 2 GPI binding proteins also must be considered when assessing the cellular responses to β 2 GPI/anti-β 2 GPI binding. 87 Annexin A2 and the annexin A2:S100A10 heterotetramer also play an important role in the regulation of cell surface fibrinolysis, and this process may be impaired by anti-annexin A2 antibodies. 12 The full impact of β 2 GPI on annexin A2-stimulated t-PA-mediated plasminogen activation has yet to be clearly defined. The fact that β 2 GPI alone may potentially stimulate this activity, and has been reported to enhance plasminogen activation following incubation with intact endothelial cells, 83 complicates this analysis. More detailed characterization of the nature of the annexin A2-β 2 GPI binding interaction may allow a more definitive investigation of this process.
